Crescent Biopharma (NASDAQ:CBIO) Lowered to Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen has downgraded Crescent Biopharma from a "hold" to a "sell" rating, highlighting a shift in analyst sentiment towards the stock.
• Despite the downgrade, other analysts have recently upgraded Crescent Biopharma, with ratings of "strong-buy" from TD Cowen and Lifesci Capital and a target price as high as $28.00.
• The company's latest earnings report showed a significant loss of ($4.93) EPS, missing expectations by over $2, indicating financial struggles.

Crescent Biopharma (NASDAQ:CBIO - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday.

A number of other research analysts also recently weighed in on the company. Wedbush assumed coverage on Crescent Biopharma in a report on Monday, July 14th. They issued an "outperform" rating and a $27.00 target price on the stock. TD Cowen upgraded Crescent Biopharma to a "strong-buy" rating in a research report on Friday, June 20th. Stifel Nicolaus began coverage on Crescent Biopharma in a research report on Wednesday, June 25th. They issued a "buy" rating and a $28.00 price target for the company. Finally, Lifesci Capital upgraded Crescent Biopharma to a "strong-buy" rating and set a $22.00 target price for the company in a research report on Wednesday, June 18th. One research analyst has rated the stock with a sell rating, two have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $25.67.

Crescent Biopharma Price Performance

Shares of NASDAQ:CBIO traded down $0.19 during midday trading on Friday, reaching $11.41. 6,925 shares of the company's stock traded hands, compared to its average volume of 39,621. The company has a market cap of $223.07 million, a P/E ratio of -0.33 and a beta of 1.51. Crescent Biopharma has a one year low of $11.06 and a one year high of $63.00.

Crescent Biopharma (NASDAQ:CBIO - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($4.93) earnings per share for the quarter, missing analysts' consensus estimates of ($2.69) by ($2.24). On average, sell-side analysts anticipate that Crescent Biopharma will post -0.16 earnings per share for the current year.

About Crescent Biopharma

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.